The use of population pharmacokinetic and pharmacodynamic modeling and simulation in anti-osteoporotic drug development: A perspective

Chihiro Hasegawa, Tomoya Ohno, Ichiro Ieiri

Research output: Contribution to journalReview article

Abstract

Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. In postmenopausal osteoporosis, estrogen deficiency increases bone turnover with an imbalance between bone resorption and formation, resulting in low bone mass and subsequent increase in bone fragility. The fractures that result from osteoporosis are a major public health problem. Developing new anti-osteoporotic treatments is challenging, because clinical studies needed to establish the efficacy of osteoporosis prevention and treatment require a long follow-up duration. Population pharmacokineticpharmacodynamic( PK-PD)modeling is the standard approach to describe relationships between dose, dosing regimen, longitudinal concentration of targeted drug, and efficacy(or response) data including biomarkers, surrogate endpoints, and clinical endpoints obtained from particular groups of subjects. These relationships are believed to be useful in predicting an optimal dosing regimen and/or study duration. A number of examples utilizing the PK-PD modeling approach in clinical drug development have been reported. In the field of osteoporosis, several modeling examples have described a series of relationships between dose, PK, bone turnover markers, bone mineral density and fracture risk(clinical endpoint). Although there are relatively few reports in which PK-PD modeling is applied to clinical drug development in osteoporosis compared to other disease areas, the number of such reports has been increasing recently. The aim of this review is to provide a perspective on effective application of population PK-PD modeling in the clinical development of anti-osteoporotic drugs by revisiting the results of PK-PD modeling used in the field of osteoporosis.

Original languageEnglish
Pages (from-to)187-196
Number of pages10
JournalJapanese Journal of Clinical Pharmacology and Therapeutics
Volume45
Issue number5
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Osteoporosis
Pharmacokinetics
Pharmaceutical Preparations
Population
Bone Remodeling
Bone and Bones
Biomarkers
Postmenopausal Osteoporosis
Bone Fractures
Bone Resorption
Osteogenesis
Bone Density
Estrogens
Public Health

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

The use of population pharmacokinetic and pharmacodynamic modeling and simulation in anti-osteoporotic drug development : A perspective. / Hasegawa, Chihiro; Ohno, Tomoya; Ieiri, Ichiro.

In: Japanese Journal of Clinical Pharmacology and Therapeutics, Vol. 45, No. 5, 01.01.2014, p. 187-196.

Research output: Contribution to journalReview article

@article{b7b332bf97c94a33961edbed9c869d66,
title = "The use of population pharmacokinetic and pharmacodynamic modeling and simulation in anti-osteoporotic drug development: A perspective",
abstract = "Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. In postmenopausal osteoporosis, estrogen deficiency increases bone turnover with an imbalance between bone resorption and formation, resulting in low bone mass and subsequent increase in bone fragility. The fractures that result from osteoporosis are a major public health problem. Developing new anti-osteoporotic treatments is challenging, because clinical studies needed to establish the efficacy of osteoporosis prevention and treatment require a long follow-up duration. Population pharmacokineticpharmacodynamic( PK-PD)modeling is the standard approach to describe relationships between dose, dosing regimen, longitudinal concentration of targeted drug, and efficacy(or response) data including biomarkers, surrogate endpoints, and clinical endpoints obtained from particular groups of subjects. These relationships are believed to be useful in predicting an optimal dosing regimen and/or study duration. A number of examples utilizing the PK-PD modeling approach in clinical drug development have been reported. In the field of osteoporosis, several modeling examples have described a series of relationships between dose, PK, bone turnover markers, bone mineral density and fracture risk(clinical endpoint). Although there are relatively few reports in which PK-PD modeling is applied to clinical drug development in osteoporosis compared to other disease areas, the number of such reports has been increasing recently. The aim of this review is to provide a perspective on effective application of population PK-PD modeling in the clinical development of anti-osteoporotic drugs by revisiting the results of PK-PD modeling used in the field of osteoporosis.",
author = "Chihiro Hasegawa and Tomoya Ohno and Ichiro Ieiri",
year = "2014",
month = "1",
day = "1",
doi = "10.3999/jscpt.45.187",
language = "English",
volume = "45",
pages = "187--196",
journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",
issn = "0388-1601",
publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",
number = "5",

}

TY - JOUR

T1 - The use of population pharmacokinetic and pharmacodynamic modeling and simulation in anti-osteoporotic drug development

T2 - A perspective

AU - Hasegawa, Chihiro

AU - Ohno, Tomoya

AU - Ieiri, Ichiro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. In postmenopausal osteoporosis, estrogen deficiency increases bone turnover with an imbalance between bone resorption and formation, resulting in low bone mass and subsequent increase in bone fragility. The fractures that result from osteoporosis are a major public health problem. Developing new anti-osteoporotic treatments is challenging, because clinical studies needed to establish the efficacy of osteoporosis prevention and treatment require a long follow-up duration. Population pharmacokineticpharmacodynamic( PK-PD)modeling is the standard approach to describe relationships between dose, dosing regimen, longitudinal concentration of targeted drug, and efficacy(or response) data including biomarkers, surrogate endpoints, and clinical endpoints obtained from particular groups of subjects. These relationships are believed to be useful in predicting an optimal dosing regimen and/or study duration. A number of examples utilizing the PK-PD modeling approach in clinical drug development have been reported. In the field of osteoporosis, several modeling examples have described a series of relationships between dose, PK, bone turnover markers, bone mineral density and fracture risk(clinical endpoint). Although there are relatively few reports in which PK-PD modeling is applied to clinical drug development in osteoporosis compared to other disease areas, the number of such reports has been increasing recently. The aim of this review is to provide a perspective on effective application of population PK-PD modeling in the clinical development of anti-osteoporotic drugs by revisiting the results of PK-PD modeling used in the field of osteoporosis.

AB - Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. In postmenopausal osteoporosis, estrogen deficiency increases bone turnover with an imbalance between bone resorption and formation, resulting in low bone mass and subsequent increase in bone fragility. The fractures that result from osteoporosis are a major public health problem. Developing new anti-osteoporotic treatments is challenging, because clinical studies needed to establish the efficacy of osteoporosis prevention and treatment require a long follow-up duration. Population pharmacokineticpharmacodynamic( PK-PD)modeling is the standard approach to describe relationships between dose, dosing regimen, longitudinal concentration of targeted drug, and efficacy(or response) data including biomarkers, surrogate endpoints, and clinical endpoints obtained from particular groups of subjects. These relationships are believed to be useful in predicting an optimal dosing regimen and/or study duration. A number of examples utilizing the PK-PD modeling approach in clinical drug development have been reported. In the field of osteoporosis, several modeling examples have described a series of relationships between dose, PK, bone turnover markers, bone mineral density and fracture risk(clinical endpoint). Although there are relatively few reports in which PK-PD modeling is applied to clinical drug development in osteoporosis compared to other disease areas, the number of such reports has been increasing recently. The aim of this review is to provide a perspective on effective application of population PK-PD modeling in the clinical development of anti-osteoporotic drugs by revisiting the results of PK-PD modeling used in the field of osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84908470871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908470871&partnerID=8YFLogxK

U2 - 10.3999/jscpt.45.187

DO - 10.3999/jscpt.45.187

M3 - Review article

AN - SCOPUS:84908470871

VL - 45

SP - 187

EP - 196

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

SN - 0388-1601

IS - 5

ER -